At present, data on serum levels of PCSK9 in IBD are inconsistent and analyses of well-described, large cohorts that can correct for confounding factors such as hypercholesterolemia and severe liver disease are needed. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.